Sequential Therapy with Gemcitabine and Carboplatin Followed by Paclitaxel as First Line Treatment for Advanced Urothelial Cancer (original) (raw)
Prospective Trial of Ifosfamide, Paclitaxel, and Cisplatin in Patients with Advanced Non-transitional Cell Carcinoma of the Urothelial Tract
Paul Russo
Urology, 2007
View PDFchevron_right
Re: Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma
Isabele Small
International braz j urol, 2007
View PDFchevron_right
Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer
Jorge garcia
Cancer, 2011
View PDFchevron_right
Second line treatment of non-small cell lung cancer with paclitaxel and gemcitabine
Nikolaos Vardakis
European Journal of Cancer, 1997
View PDFchevron_right
Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors
Vicente Alfaro
Cancer, 2007
View PDFchevron_right
Primary chemotherapy with low-dose prolonged infusion gemcitabine and cisplatin in patients with bladder cancer: A Phase II trial
Ahmed Warith
Urologic Oncology: Seminars and Original Investigations, 2008
View PDFchevron_right
Optimal Management of Upper Tract Urothelial Carcinoma: an Unmet Need
Yee Mun Lee
Current Treatment Options in Oncology, 2019
View PDFchevron_right
Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study
Nikolaos Vardakis
Cancer Chemotherapy and Pharmacology, 2012
View PDFchevron_right
Saudi oncology society and Saudi urology association combined clinical management guidelines for urothelial urinary bladder cancer
Abdullah Alghamdi
Urology Annals, 2014
View PDFchevron_right
Efficacy of methotrexate/vinblastine/doxorubicin/cisplatin combination in gemcitabine-pretreated patients with advanced urothelial cancer: a retrospective analysis
Aristotelis Bamias
Open Access Journal of Urology, 2010
View PDFchevron_right
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)
Aristotelis Bamias
Annals of Oncology, 2012
View PDFchevron_right
An update on immunotherapy in uro-oncology
Alessia Cimadamore
Expert Review of Precision Medicine and Drug Development, 2021
View PDFchevron_right
Phase II trial of paclitaxel and uracil–tegafur in metastatic breast cancer. TEGATAX trial
tri nguyen
The Breast, 2011
View PDFchevron_right
Seeking the solution to the problem of metastatic renal carcinoma
Paul Russo
Cancer, 2003
View PDFchevron_right
Phase II Multicenter Trial with Carboplatin and Gemcitabine Induction Chemotherapy Followed by Radiotherapy Concomitantly with Low-Dose Paclitaxel and Gemcitabine for Stage IIIA and IIIB Non-small Cell Lung Cancer
Jim Gruber
Journal of Thoracic Oncology, 2007
View PDFchevron_right
Melphalan-Flufenamide is Cytotoxic and Potentiates Treatment with Chemotherapy and the Src Inhibitor Dasatinib in Urothelial Cancer
Petra Hååg
Molecular Oncology, 2016
View PDFchevron_right
Urinary Tract Large Cell Neuroendocrine Carcinoma
Alessia Cimadamore
Encyclopedia of Pathology, 2020
View PDFchevron_right
A phase II study of carboplatin in metastatic transition cell carcinoma of the bladder
Tiara Dipa
European Journal of Cancer and Clinical Oncology, 1987
View PDFchevron_right
Ureterocele urothelial carcinoma: managing a rare presentation
Juan Carlos Astigueta
ecancermedicalscience, 2016
View PDFchevron_right
Toxic erythema of chemotherapy secondary to gemcitabine and paclitaxel
Erin Jennings
Dermatology Online Journal, 2020
View PDFchevron_right
Bladder cancer
Öner M Şanlı
Nature Reviews Disease Primers, 2017
View PDFchevron_right
Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer
Andrea Alberto Lissoni
Annals of Oncology, 1996
View PDFchevron_right
Targeted Triple Drug Regimen for the Treatment of Prostate Cancer
Tanuja Tummala
2018
View PDFchevron_right
Kidney Cancer, Version 3.2015
Steven Hancock
View PDFchevron_right
Cutting Edge Therapies for Cancer in the 21st Century
PARASKEVI V VOGIATZI
2014
View PDFchevron_right
Prognosis of Patients Receiving Chemotherapy for Metastatic Upper Tract Urothelial Carcinoma Compared With Metastatic Urinary Bladder Cancer
Hirotsugu Uemura
Cancer Diagnosis & Prognosis, 2023
View PDFchevron_right
A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer
Michael Carducci
Urologic Oncology: Seminars and Original Investigations, 2004
View PDFchevron_right
Muscle-invasive bladder cancer
Adam Landau
2014
View PDFchevron_right
Tumor Regression Grade of Urothelial Bladder Cancer After Neoadjuvant Chemotherapy
Achim Fleischmann
American Journal of Surgical Pathology, 2014
View PDFchevron_right
Focus on prostate cancer
Angelo Marzo
Cancer Cell, 2002
View PDFchevron_right
Recent progress in cancer therapeutics
Michael Rossbach
Translational oncology, 2009
View PDFchevron_right
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours
Elisa Gallerani
European Journal of Cancer, 2008
View PDFchevron_right
Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder
Pedro Boria
Veterinary and Comparative Oncology, 2005
View PDFchevron_right
Recent Advances in Cancer Therapy: An Overview
Francesc Viñals
Current Pharmaceutical Design, 2010
View PDFchevron_right
Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987
Gedske Daugaard
Journal of Clinical Oncology, 2012
View PDFchevron_right